Ifosfamide with mesna uroprotection in the management of lung cancer

P. Y. Holoye; B. S. Glisson; J. S. Lee; H. M. Dhingra; W. K. Murphy; T. Umsawasdi; J. K. Levy; D. Jeffries; M. N. Raber; W. K. Hong

doi:10.1097/00000421-199004000-00012

Ifosfamide with mesna uroprotection in the management of lung cancer

P. Y. Holoye, B. S. Glisson, J. S. Lee, H. M. Dhingra, W. K. Murphy, T. Umsawasdi, J. K. Levy, D. Jeffries, M. N. Raber, W. K. Hong

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

Fourteen patients with extensive disease small cell bronchogenic carcinoma (SCBC) received ifosfamide at 2,000 mg/m²/day for 5 consecutive days with simultaneous mesna and vincristine while 26 patients with extensive disease non-small-cell bronchogenic carcinoma (N-SCBC) received the same regimen without vincristine. Eight partial responses (57%) were observed with a 40-week median survival in the case of SCBC and four partial remissions (15%) with a 31-week median survival in N-SCBC. Granulocytopenia was the dose -limiting toxicity, whereas urotoxicity was well controlled with mesna. Neuropsychiatric toxicity consisted of anxiety, agitation, confusion, and hallucination. Neurobehavioral testing detected worsened performance during ifosfamide treatment. Ifosfamide is one of the few active agents in N-SCBC.

Original language	English (US)
Pages (from-to)	148-155
Number of pages	8
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	13
Issue number	2
DOIs	https://doi.org/10.1097/00000421-199004000-00012
State	Published - 1990

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1097/00000421-199004000-00012

Cite this

@article{c8337bf900b44b2f8fba62d82c4d9aac,

title = "Ifosfamide with mesna uroprotection in the management of lung cancer",

abstract = "Fourteen patients with extensive disease small cell bronchogenic carcinoma (SCBC) received ifosfamide at 2,000 mg/m2/day for 5 consecutive days with simultaneous mesna and vincristine while 26 patients with extensive disease non-small-cell bronchogenic carcinoma (N-SCBC) received the same regimen without vincristine. Eight partial responses (57%) were observed with a 40-week median survival in the case of SCBC and four partial remissions (15%) with a 31-week median survival in N-SCBC. Granulocytopenia was the dose -limiting toxicity, whereas urotoxicity was well controlled with mesna. Neuropsychiatric toxicity consisted of anxiety, agitation, confusion, and hallucination. Neurobehavioral testing detected worsened performance during ifosfamide treatment. Ifosfamide is one of the few active agents in N-SCBC.",

author = "Holoye, {P. Y.} and Glisson, {B. S.} and Lee, {J. S.} and Dhingra, {H. M.} and Murphy, {W. K.} and T. Umsawasdi and Levy, {J. K.} and D. Jeffries and Raber, {M. N.} and Hong, {W. K.}",

year = "1990",

doi = "10.1097/00000421-199004000-00012",

language = "English (US)",

volume = "13",

pages = "148--155",

journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Ifosfamide with mesna uroprotection in the management of lung cancer

AU - Holoye, P. Y.

AU - Glisson, B. S.

AU - Lee, J. S.

AU - Dhingra, H. M.

AU - Murphy, W. K.

AU - Umsawasdi, T.

AU - Levy, J. K.

AU - Jeffries, D.

AU - Raber, M. N.

AU - Hong, W. K.

PY - 1990

Y1 - 1990

N2 - Fourteen patients with extensive disease small cell bronchogenic carcinoma (SCBC) received ifosfamide at 2,000 mg/m2/day for 5 consecutive days with simultaneous mesna and vincristine while 26 patients with extensive disease non-small-cell bronchogenic carcinoma (N-SCBC) received the same regimen without vincristine. Eight partial responses (57%) were observed with a 40-week median survival in the case of SCBC and four partial remissions (15%) with a 31-week median survival in N-SCBC. Granulocytopenia was the dose -limiting toxicity, whereas urotoxicity was well controlled with mesna. Neuropsychiatric toxicity consisted of anxiety, agitation, confusion, and hallucination. Neurobehavioral testing detected worsened performance during ifosfamide treatment. Ifosfamide is one of the few active agents in N-SCBC.

AB - Fourteen patients with extensive disease small cell bronchogenic carcinoma (SCBC) received ifosfamide at 2,000 mg/m2/day for 5 consecutive days with simultaneous mesna and vincristine while 26 patients with extensive disease non-small-cell bronchogenic carcinoma (N-SCBC) received the same regimen without vincristine. Eight partial responses (57%) were observed with a 40-week median survival in the case of SCBC and four partial remissions (15%) with a 31-week median survival in N-SCBC. Granulocytopenia was the dose -limiting toxicity, whereas urotoxicity was well controlled with mesna. Neuropsychiatric toxicity consisted of anxiety, agitation, confusion, and hallucination. Neurobehavioral testing detected worsened performance during ifosfamide treatment. Ifosfamide is one of the few active agents in N-SCBC.

UR - http://www.scopus.com/inward/record.url?scp=0025301720&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025301720&partnerID=8YFLogxK

U2 - 10.1097/00000421-199004000-00012

DO - 10.1097/00000421-199004000-00012

M3 - Article

C2 - 2156418

AN - SCOPUS:0025301720

SN - 0277-3732

VL - 13

SP - 148

EP - 155

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

IS - 2

ER -

Ifosfamide with mesna uroprotection in the management of lung cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this